Tempus AI
NativeApplied AIPublic · TEMUpdated November 15, 2026The company sitting on the most valuable clinical dataset in AI — and building a real business on top of it.
- Website
- tempus.com
- Founded
- 2015
- CEO
- Eric Lefkofsky
- HQ
- Chicago, IL, United States
- Stage
- Public
- Revenue
- $1B–$10B
- Employees
- 1001-5000
Executive Summary
Updated Nov 15, 2026
What they do
- Runs genomic testing for cancer, including xT CDx and MRD tests, at national scale
- Licenses de-identified multimodal clinical and molecular data to pharma for research
- Builds FDA-cleared ECG-AI devices, pathology AI and AI tools that support doctors' decisions
Why it matters
- Q3 2026 revenue reached a record $411.5M; 2026 guidance is about $1.6B
- Pharma backing includes AstraZeneca, Bristol-Myers Squibb and Recursion data and model agreements
- Paige and the pending Personalis deal deepen its pathology AI and MRD offerings
Best fit
- Pharma and biotech teams that need real-world oncology data for R&D
- Health systems and oncology practices that want genomic testing linked to decision support
- Cardiology programs adopting FDA-cleared ECG-AI screening for undiagnosed heart disease
Watch-outs
- 2026 class actions over alleged unlawful disclosure of patients' genetic data
- Still loss-making on GAAP, with adjusted EBITDA guidance of only about $65M for 2026
- Integrating the $1.5B Personalis all-stock deal may distract execution and dilute shareholders
Products & Offerings
Tempus Genomics (xT CDx, xF, xR, MRD)
Tumor and liquid-biopsy genomic profiling and molecular residual disease tests for precision oncology, including the FDA-approved xT CDx.
Tempus Data & Services (Insights / Lens)
Licensing of de-identified multimodal real-world clinical and molecular data, plus analytics tools for pharma and biotech R&D.
Tempus One
Generative AI clinical assistant that gives physicians fast access to patient test results, records and treatment insights.
Tempus ECG-AI
FDA-cleared AI software that detects atrial fibrillation risk, low ejection fraction, pulmonary hypertension and mitral regurgitation from standard ECGs.
Paige Digital Pathology
AI pathology products and an oncology foundation model, acquired with Paige in 2025 for $81.25M.
Latest News
Yahoo Finance · 1 day ago
NeutralTipRanks · 1 day ago
PositiveSmartkarma · 1 day ago
NeutralMedical Dialogues · 2 days ago
Positivekalkine.ca · 2 days ago
NeutralUpdated Nov 15, 2026
Tempus is one of the largest and most proven AI-driven precision oncology vendors, with fast revenue growth, multiple FDA-cleared products and major pharma data partnerships. Pharma R&D teams and health systems buying oncology genomics or real-world data should include it, alongside Foundation Medicine, Guardant, Caris and Flatiron. Before committing, check its data-governance and consent practices given the 2026 genetic-data litigation, and get contract protections in case the Personalis integration disrupts service.
Signal Provenance
Latest observation date and source for each signal category
| Signal Category | Last Updated | Source |
|---|---|---|
Funding Signals Last funding round, Funding stage | Nov 12, 2026 | Cited web research |
Hiring Velocity Headcount, Headcount growth | Nov 15, 2026 | Research agents (estimate) |
Technical Output Research papers, GitHub activity | Nov 11, 2026 | Hugging Face Hub + news feed + research agents |
News Sentiment News mentions, News sentiment | Nov 15, 2026 | Verified news feed |
Partnership Signals Enterprise partnerships, Distribution partners | Nov 12, 2026 | Research agents (estimate) |
Revenue Indicators ARR estimate, Revenue growth | Nov 15, 2026 | SEC filings |
Leadership Signals CEO tenure, Founder-led | Nov 15, 2026 | Research agents (estimate) |
Competitive Position Category rank, Market share | Nov 15, 2026 | Research agents (estimate) |
Why this Bluescore?
6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology
Tempus AI's Bluescore of 57.2 rests most on Investment Momentum (9.0, top 3%) and Data & Model Moat (6.8, top 11%). Its weakest area is Product Depth (4.2, 38th percentile).
In plain English
Tempus AI's Bluescore of 57.2 places it at #58 of 247, with its strongest contributions coming from Investment Momentum at 9.0 of 10 (97th percentile), Data & Model Moat at 6.8 of 10 (89th percentile), and Business Model & Revenue at 6.3 of 10 (82nd percentile). The biggest drag is Product Depth, which scores 4.2 of 10 (38th percentile) on a 21% weight and still has 12.1 points left, the largest gap of any dimension. Improving Product Depth would move the Bluescore more than any other change, because it carries a large weight and is currently one of the weakest scores.
Written by AI from the scores below and checked against them; updated nightly.
Traction Signals
Last Round
Public
Risks
Updated Nov 15, 2026